Kinsight LLC Sells 1,197 Shares of Johnson & Johnson (JNJ)
Kinsight LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 30.9% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 2,673 shares of the company’s stock after selling 1,197 shares during the period. Johnson & Johnson comprises 0.2% of Kinsight LLC’s investment portfolio, making the stock its 19th largest holding. Kinsight LLC’s holdings in Johnson & Johnson were worth $354,000 as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also made changes to their positions in JNJ. Lynch & Associates IN increased its position in shares of Johnson & Johnson by 0.9% in the 2nd quarter. Lynch & Associates IN now owns 93,710 shares of the company’s stock valued at $12,397,000 after purchasing an additional 841 shares during the last quarter. Oakbrook Investments LLC increased its position in shares of Johnson & Johnson by 7.4% in the 2nd quarter. Oakbrook Investments LLC now owns 136,124 shares of the company’s stock valued at $18,008,000 after purchasing an additional 9,375 shares during the last quarter. Trexquant Investment LP purchased a new stake in shares of Johnson & Johnson in the 1st quarter valued at approximately $1,731,000. Bollard Group LLC increased its position in shares of Johnson & Johnson by 5.0% in the 2nd quarter. Bollard Group LLC now owns 9,551 shares of the company’s stock valued at $1,263,000 after purchasing an additional 459 shares during the last quarter. Finally, Adams Diversified Equity Fund Inc. increased its position in shares of Johnson & Johnson by 278.0% in the 2nd quarter. Adams Diversified Equity Fund Inc. now owns 241,900 shares of the company’s stock valued at $32,001,000 after purchasing an additional 177,900 shares during the last quarter. 65.90% of the stock is currently owned by hedge funds and other institutional investors.
In other Johnson & Johnson news, VP Dominic J. Caruso sold 82,591 shares of the business’s stock in a transaction on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the completion of the sale, the vice president now owns 226,693 shares in the company, valued at $30,993,466.96. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, VP Paulus Stoffels sold 102,692 shares of the business’s stock in a transaction on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the sale, the vice president now owns 230,342 shares of the company’s stock, valued at approximately $30,667,733.88. The disclosure for this sale can be found here. 0.19% of the stock is owned by insiders.
A number of equities research analysts have commented on JNJ shares. BidaskClub raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Royal Bank Of Canada reissued a “buy” rating and issued a $128.00 price objective on shares of Johnson & Johnson in a research report on Thursday, June 15th. Atlantic Securities downgraded shares of Johnson & Johnson from a “neutral” rating to an “underweight” rating and set a $113.00 price objective on the stock. in a research report on Friday, July 21st. Jefferies Group LLC reissued a “hold” rating and issued a $145.00 price objective (up from $140.00) on shares of Johnson & Johnson in a research report on Friday, July 14th. Finally, Citigroup Inc. started coverage on shares of Johnson & Johnson in a research report on Monday, September 25th. They issued a “neutral” rating and a $140.00 price objective on the stock. Five equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eight have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $134.79.
Shares of Johnson & Johnson (JNJ) traded up 0.02% during mid-day trading on Friday, reaching $133.22. 3,024,247 shares of the company were exchanged. The firm has a market capitalization of $357.56 billion, a price-to-earnings ratio of 22.39 and a beta of 0.78. The company’s 50-day moving average is $132.23 and its 200 day moving average is $129.87. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 18th. The company reported $1.83 earnings per share for the quarter, beating the consensus estimate of $1.79 by $0.04. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm had revenue of $18.84 billion during the quarter, compared to analyst estimates of $18.94 billion. During the same quarter in the previous year, the firm earned $1.74 earnings per share. The firm’s revenue for the quarter was up 1.9% compared to the same quarter last year. Analysts predict that Johnson & Johnson will post $7.18 EPS for the current year.
The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were paid a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.52%. Johnson & Johnson’s payout ratio is 56.76%.
ILLEGAL ACTIVITY WARNING: “Kinsight LLC Sells 1,197 Shares of Johnson & Johnson (JNJ)” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/10/08/kinsight-llc-sells-1197-shares-of-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Receive News & Stock Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related stocks with our FREE daily email newsletter.